PharmiWeb.com - Global Pharma News & Resources
19-Jul-2019

Irritable Bowel Syndrome Treatment Market Will Grow 9.8% to a Record $ 3.4 Billion by 2026

The Global Irritable Bowel Syndrome Treatment Market Size is anticipated to around USD 3.4 billion by 2026, this market is anticipated to grow with 9.8% CAGR during the forecast time period 2019 to 2026. Acumen Research and Consulting, Recently Published Report titled ldquo;Irritable Bowel Syndrome Treatment Market Size, Share, Trends, Growth and Forecast 2019-2026rdquo;.

The growing incidence of target diseases and the expansion of current medicines labels are expected to accelerate market growth. Furthermore, increasing use of medicines and the launch of new goods are expected to drive the market for IBS (Irritable Bowel Syndrome).

IBS is one of the most popular gastrointestinal illnesses with a incidence of 10-15% globally. Most IBS individuals are under the age of 50 but many elderly people also suffer. The impact of this disease may range from mild discomfort to severe weakness. It can regulate several aspects of the professional, emotional and social lives of a patient. Moderate to serious patients typically have symptoms which often adversely affect their mental, physical, educational, social, and financial well-being.

Symptoms may differ, and constipation may alternate with diarrhea, sometimes contradictory. These variables add to the need for irritable bowel syndrome treatments which allow patients to continue with their daily lives. The syndrome of long term patients is likely to disrupt their private and professional operations, and normally limits their potential.

Roughly 40% of patients suffer from mild IBS, 35% have moderate IBS, and 25% have serious IBS. Many individuals are unable to differentiate between IBS symptoms; it is still one of the most frequent illnesses that doctors are diagnosed. Not all people with IBS symptoms have the same therapy. However, approximately 2.4 to 3.5 million doctor calls are given annually in the United States alone for irritable bowel syndrome. It impacts approximately 35ndash;40% of men and 60%ndash;65% of women worldwide.

Free Download Sample Report Pages for Better Understanding at https://www.acumenresearchandconsulting.com/request-sample/1528

Key Highlights

Due to the increasing incidence and increasing intake of medication such as Linzess / Constella and Amitiza, IBS-C was the biggest producing income segment per form in 2018.

Due to increased product acceptance in significant areas like the U.S., Germany, U.K., Italy, Spain, and Japan, Linzess / Constella was in 2018 the market leader on the worldwide IBS therapy market.

The biggest income-generating region in 2018, North America was projected to be, followed by Europe. The main contributors are the presence of important players in the industry, the elevated level of attention to patients, the powerful presence of new products and the established health infrastructure.

Over the forecast period, Europe is expected to be the fastest developing region. Increased marketing and the existence of a big target population drive the IBS therapy market.

Players have adopted policies to boost their market share, such as extension of products, product growth, regional expansion, and fusions and acquisitions. In April 2015, the company purchased a portfolio focused on gastrointestinal medicines by Salix Pharmaceuticals.

Irritable bowel syndrome is a gastrointestinal functional intestinal disorder which may be defined by contractions of the colon muscle. The big intestine is affected by irritable bowel syndrome. Irritable bowel syndrome is caused by bowel dysfunction and is mostly present in the elderly.

Key Players amp; Strategies

Some of the key players in the market are Allergan; Ironwood Pharmaceuticals, Inc.; Synergy Pharmaceuticals Inc., Bausch Health; Takeda Pharmaceutical Company Limited AstraZeneca; Sebela Pharmaceuticals Inc.; Synthetic Biologics, Inc.; Astellas Pharma, Inc.; and Ardelyx. The main players have adopted distinct approaches for increasing their market share, such as mergers and acquisitions. In April 2015, for example, Bausch Health purchased a portfolio of Salix Pharmaceuticals focusing on gastrointestinal medicine.

In order to expands its market presence, players are also focused on launching their products in distinct areas. Ironwood Pharmaceuticals and AstraZeneca obtained marketing permission for Linzess in China in January 2019, for example, to enhance their market position.

View Detail Information at https://www.acumenresearchandconsulting.com/irritable-bowel-syndrome-treatment-market

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Irritable Bowel Syndrome Treatment
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Irritable Bowel Syndrome Treatment Market By Type
1.2.2.1. Global Irritable Bowel Syndrome Treatment Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.2.2. Global Irritable Bowel Syndrome Treatment Market Revenue Share By Type in 2017
1.2.2.3. IBS-D
1.2.2.3.1. Viberzi
1.2.2.3.2. Xifaxan
1.2.2.3.3. Others
1.2.2.4. IBS-C
1.2.2.4.1. Amitiza
1.2.2.4.2. Linzess/Constella
1.2.2.4.3. Others
1.2.3. Irritable Bowel Syndrome Treatment Market By Product
1.2.3.1. Global Irritable Bowel Syndrome Treatment Market Revenue and Growth Rate Comparison By Product (2015-2026)
1.2.3.2. Global Irritable Bowel Syndrome Treatment Market Revenue Share By Product in 2017
1.2.3.3. Viberzi
1.2.3.4. Linzess/Constella
1.2.3.5. Xifaxan
1.2.3.6. Amitiza
1.2.3.7. Others
1.2.4. Irritable Bowel Syndrome Treatment Market by Geography
1.2.4.1. Global Irritable Bowel Syndrome Treatment Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.4.2. North America Irritable Bowel Syndrome Treatment Market Revenue and Growth Rate (2015-2026)
1.2.4.3. Europe Irritable Bowel Syndrome Treatment Market Revenue and Growth Rate (2015-2026)
1.2.4.4. Asia-Pacific Irritable Bowel Syndrome Treatment Market Revenue and Growth Rate (2015-2026)
1.2.4.5. Latin America Irritable Bowel Syndrome Treatment Market Revenue and Growth Rate (2015-2026)
1.2.4.6. Middle East and Africa (MEA) Irritable Bowel Syndrome Treatment Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porterrsquo;s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Irritable Bowel Syndrome Treatment Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Irritable Bowel Syndrome Treatment Major Manufacturers in 2017
3.3. Ramp;D Status and Technology Source of Global Irritable Bowel Syndrome Treatment Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Irritable Bowel Syndrome Treatment Major Manufacturers in 2017

CHAPTER 4. IRRITABLE BOWEL SYNDROME TREATMENT MARKET BY TYPE

4.1. Global Irritable Bowel Syndrome Treatment Revenue By Type
4.2. IBS-D
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.2.3. Viberzi
4.2.4. Xifaxan
4.2.5. Others
4.3. IBS-C
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3.3. Amitiza
4.3.4. Linzess/Constella
4.3.5. Others

CHAPTER 5. IRRITABLE BOWEL SYNDROME TREATMENT MARKET BY PRODUCT

5.1. Global Irritable Bowel Syndrome Treatment Revenue By Product
5.2. Viberzi
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Linzess/Constella
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Xifaxan
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Amitiza
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.6. Others
5.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET BY COUNTRY

6.1. North America Irritable Bowel Syndrome Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2. North America Irritable Bowel Syndrome Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
6.3. U.S.
6.3.1. U.S. Irritable Bowel Syndrome Treatment Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
6.4. Canada
6.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
6.5. Mexico
6.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)

CHAPTER 7. EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET BY COUNTRY

7.1. Europe Irritable Bowel Syndrome Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. Europe Irritable Bowel Syndrome Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
7.3. UK
7.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
7.4. Germany
7.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
7.5. France
7.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
7.6. Spain
7.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.6.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
7.7. Rest of Europe
7.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.7.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)

CHAPTER 8. ASIA-PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET BY COUNTRY

8.1. Asia-Pacific Irritable Bowel Syndrome Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Asia-Pacific Irritable Bowel Syndrome Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
8.3. China
8.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.4. Japan
8.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.5. India
8.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.6. Australia
8.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.7. South Korea
8.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.8. Rest of Asia-Pacific
8.8.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.8.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)

CHAPTER 9. LATIN AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET BY COUNTRY

9.1. Latin America Irritable Bowel Syndrome Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Latin America Irritable Bowel Syndrome Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
9.3. Brazil
9.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.4. Argentina
9.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.5. Rest of Latin America
9.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)

CHAPTER 10. MIDDLE EAST IRRITABLE BOWEL SYNDROME TREATMENT MARKET BY COUNTRY

10.1. Middle East Irritable Bowel Syndrome Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Middle East Irritable Bowel Syndrome Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
10.3. Saudi Arabia
10.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
10.4. UAE
10.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
10.5. Rest of Middle East
10.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)

CHAPTER 11. AFRICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET BY COUNTRY

11.1. Africa Irritable Bowel Syndrome Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Africa Irritable Bowel Syndrome Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
11.3. South Africa
11.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
11.4. Egypt
11.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
11.5. Rest of Africa
11.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)

CHAPTER 12. COMPANY PROFILE

12.1. Allergan
12.1.1. Company Snapshot
12.1.2. Overview
12.1.3. Financial Overview
12.1.4. Product Portfolio
12.1.5. Key Developments
12.1.6. Strategies
12.2. Ironwood Pharmaceuticals, Inc.
12.2.1. Company Snapshot
12.2.2. Overview
12.2.3. Financial Overview
12.2.4. Product Portfolio
12.2.5. Key Developments
12.2.6. Strategies
12.3. Synergy Pharmaceuticals Inc.
12.3.1. Company Snapshot
12.3.2. Overview
12.3.3. Financial Overview
12.3.4. Product Portfolio
12.3.5. Key Developments
12.3.6. Strategies
12.4. Bausch Health
12.4.1. Company Snapshot
12.4.2. Overview
12.4.3. Financial Overview
12.4.4. Product Portfolio
12.4.5. Key Developments
12.4.6. Strategies
12.5. Takeda Pharmaceutical Company Limited AstraZeneca
12.5.1. Company Snapshot
12.5.2. Overview
12.5.3. Financial Overview
12.5.4. Product Portfolio
12.5.5. Key Developments
12.5.6. Strategies
12.6. Sebela Pharmaceuticals Inc.
12.6.1. Company Snapshot
12.6.2. Overview
12.6.3. Financial Overview
12.6.4. Product Portfolio
12.6.5. Key Developments
12.6.6. Strategies
12.7. Synthetic Biologics, Inc.
12.7.1. Company Snapshot
12.7.2. Overview
12.7.3. Financial Overview
12.7.4. Product Portfolio
12.7.5. Key Developments
12.7.6. Strategies
12.8. Astellas Pharma, Inc.
12.8.1. Company Snapshot
12.8.2. Overview
12.8.3. Financial Overview
12.8.4. Product Portfolio
12.8.5. Key Developments
12.8.6. Strategies
12.9. Ardelyx
12.9.1. Company Snapshot
12.9.2. Overview
12.9.3. Financial Overview
12.9.4. Product Portfolio
12.9.5. Key Developments
12.9.6. Strategies
12.10. Others
12.10.1. Company Snapshot
12.10.2. Overview
12.10.3. Financial Overview
12.10.4. Product Portfolio
12.10.5. Key Developments
12.10.6. Strategies

CHAPTER 13. RESEARCH APPROACH

13.1. Research Methodology
13.1.1. Initial Data Search
13.1.2. Secondary Research
13.1.3. Primary Research
13.2. Assumptions and Scope

Request for Customization at https://www.acumenresearchandconsulting.com/request-customization/1528

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this Premium Research Report at https://www.acumenresearchandconsulting.com/buy-now/0/1528

Would like to place an order or any question, please feel free to contact atsales@acumenresearchandconsulting.com| +1 407 915 4157

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to makefact baseddecisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

Editor Details

Last Updated: 19-Jul-2019